AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Clonal Hematopoiesis and NETs Formation in Venous Thrombosis (CLODETTE)

RecruitingNAAges 6 Years - 50 YearsAllUniversity Hospital, Bordeaux
💬

In plain words

What the trial is, and whether it could suit you

Thrombo-embolic venous diseases are represented by deep venous thrombosis and/or pulmonary embolism. In some patients with repeated thrombosis or occurrence of thrombosis in unusual sites, the etiological workup remains negative, which represents a problem for the management of the anticoagulant treatments. Recently, two factors have been identified as important in the physiopathology of hemostasis and coagulation: the presence of clonal hematopoiesis of indetermined potential (CHIP) and the formation of neutrophil extracellular traps (NETs). In this study, these two factors will be studied in patients with repeated venous thrombosis or thrombosis occurring in unusual site.

Sign in to get the eligibility rules as simple questions to take to your doctor.

📋 Eligibility rules (as published)
Inclusion Criteria: * Patients (male or female) less than 50 y.o with : * Splanchnic venous territory thrombosis or * Cerebral venous thrombosis or * Venous thrombosis of the upper limb or * Pulmonary embolism (1st episode if male, 2nd episode if female) unprovoked or * 1 episode of deep vein thrombosis + 1 episode of arterial thrombosis Exclusion Criteria: * Presence of a major or minor transient venous thrombosis risk factor: * Surgery within the last 3 months preceding the qualifying thrombotic episode * Lower limb fracture with immobilization \> 3 days in the last 3 months preceding the qualifying thrombotic episode * Presence of estro-progestational contraception * Pregnancy * Immobilization for acute medical reasons within the last 3 months preceding the qualifying thrombotic episode * Air or car travel \> 6 hours * Presence of a major or minor persistent risk factor for venous thrombosis: * Presence of active cancer (solid cancer or hematologic malignancy) * Chronic inflammatory digestive or joint diseases * Ongoing treatment with heparin (low molecular weight heparin (LMWH) or unfractionated heparin (UFH)) * Presence of an abnormality on the thrombophilia test among the following abnormalities * Protein C deficiency * Protein S deficiency * Anti-thrombin deficiency * Heterozygous or homozygous factor II mutation * Heterozygous or homozygous factor V mutation * Presence of anti-phospholipid syndrome * Presence of myeloproliferative neoplasia * Presence of paroxysmal nocturnal hemoglobinuria
💊

What it tests

  • Additional blood sampling
📍

Where

7 sites
CHU de Bordeaux, Service de Neurologie
Bordeaux, France
CHU de Bordeaux, Service Gastro-Entérologie
Bordeaux, France
CHU de Bordeaux, Service Hématologie Biologique
Bordeaux, France
CHU de Bordeaux, Service Médecine Vasculaire
Bordeaux, France
CHU de Bordeaux, Unité ambulatoire de Médecine Vasculaire
Bordeaux, France
CHU de Lille, Service Hémostase Clinique
Lille, France
APHM - Hôpital de la Timone, Service Hématologie
Marseille, France
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy